# Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

> **NCT04338282** · PHASE2 · UNKNOWN · sponsor: **Beijing Tongren Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** toripalimab

## Key facts

- **NCT ID:** NCT04338282
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338282, "Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04338282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*